Program

DOWNLOAD
13th september
14th september
15th september
13th september
13 September 2023
08:00

Registration

13 September
Time:  08:00 - 09:00
Location: 
08:45

Opening presentation / Welcome speech (Eugenio Santos, Director, Centro de Investigación del Cáncer, Salamanca, Spain)

13 September
Time:  08:45 - 09:00
Location: 
09:00

SESSION 1: RAS DRIVEN MECHANISMS DURING TUMOUR INITIATION & PROGRESSION - Chairperson: Eugenio Santos

13 September
Time:  09:00 - 10:30
Location: 
09:00

Challenges and opportunities in treating KRAS mutant tumors

Shiva Malek
Targeting RAS
13 September
Time:  09:00 - 09:30
Location: 
Speaker:  Shiva Malek
09:30

RAS mutation tropism

Christopher Counter
Targeting RAS
13 September
Time:  09:30 - 10:00
Location: 
Speaker:  Christopher Counter
10:00

Disruption of Immune Homeostasis Circuits in Mutant KRas Tumors

Dafna Bar-Sagi
Targeting RAS
13 September
Time:  10:00 - 10:30
Location: 
Speaker:  Dafna Bar-Sagi
10:30

Short talk selected from abstracts | Olesja Popow, Dana-Farber Cancer Institute, Boston, USA “Dissecting The Tissue-Specific Oncogenic Activity Of K-RasG12D”

13 September
Time:  10:30 - 10:45
Location: 
10:45

Coffee break

13 September
Time:  10:45 - 11:15
Location: 
11:15

SESSION 2: RAS & TUMOUR MICROENVIRONMENT - Chairperson: Esther Castellano

13 September
Time:  11:15 - 12:45
Location: 
11:15

Developing rational approaches to targeting RAS in combination with immune regulators

Julian Downward
Targeting RAS
13 September
Time:  11:15 - 11:45
Location: 
Speaker:  Julian Downward
11:45

KRAS dependencies in Pancreatic Cancer

David Tuveson
Targeting RAS
13 September
Time:  11:45 - 12:15
Location: 
Speaker:  David Tuveson
12:15

Enhancing immunotherapy in Kras driven lung cancer

Kairbaan Hodivala-Dilke
Targeting RAS
13 September
Time:  12:15 - 12:45
Location: 
Speaker:  Kairbaan Hodivala-Dilke
12:45

Short talk selected from abstracts | Alejandro Rosell, Instituto de Biología Molecular y Celular del Cáncer, Salamanca, Spain “RAS-PI3K signaling: a master regulator of CAF phenotype to promote lung tumor progression”

13 September
Time:  12:45 - 13:00
Location: 
13:00

Lunch & poster session

13 September
Time:  13:00 - 14:30
Location: 
14:30

SESSION 3: RAS MEMBRANE DYNAMICS & STRUCTURAL INSIGHTS - Chairperson: David Santamaría

13 September
Time:  14:30 - 16:00
Location: 
14:30

How can same-gene mutations promote both cancer and developmental disorders?

Ruth Nussinov
Targeting RAS
13 September
Time:  14:30 - 15:00
Location: 
Speaker:  Ruth Nussinov
15:00

Biological relevance of KRAS complexes interaction at the cell membrane

Chiara Ambrogio
Targeting RAS
13 September
Time:  15:00 - 15:30
Location: 
Speaker:  Chiara Ambrogio
15:30

Drug combinations with novel PDE6D inhibitors release differentiation block of oncogenic KRAS

Daniel Abankwa
Targeting RAS
13 September
Time:  15:30 - 16:00
Location: 
Speaker:  Daniel Abankwa
16:00

Short talk selected from abstracts | Milla Kurki, University of Eastern Finland, Finland “Exploring mutation-specific differences of KRAS: conformational dynamics and implications for effector-protein preferences”

13 September
Time:  16:00 - 16:15
Location: 
16:15

Coffee break

13 September
Time:  16:15 - 16:45
Location: 
16:45

SESSION 4: RAS ISOFORMS AND SUPERFAMILY - Chairperson: Piero Crespo

13 September
Time:  16:45 - 18:15
Location: 
16:45

Ras variant abundance and biology

Ian Prior
Targeting RAS
13 September
Time:  16:45 - 17:15
Location: 
Speaker:  Ian Prior
17:15

Proteomic profiling of KRAS signaling; Context, CAFs and Combinations

Udai Banerji
Targeting RAS
13 September
Time:  17:15 - 17:45
Location: 
Speaker:  Udai Banerji
17:45

«Out of the box» functions of RHOA mutations in peripheral T cell lymphoma

Xosé R. Bustelo
Targeting RAS
13 September
Time:  17:45 - 18:15
Location: 
Speaker:  Xosé R. Bustelo
18:15

Short talk selected from abstracts I | Greg G Jones, Pfizer, San Diego, California, USA “Targeting the RAS Pathway through a First-in-Class DOCK5 Degrader”

13 September
Time:  18:15 - 18:30
Location: 
18:30

Short talk selected from abstracts II | Fernando Calvo Baltanas, Instituto de Biomedicina de Sevilla (IBiS), Seville, Spain “Single and dual SOS1/SOS2 inhibition: evaluation of therapeutic effects and toxicity”

13 September
Time:  18:30 - 19:15
Location: 
18:45

End of day 1

13 September
Time:  18:4500:58
14th september
14 September 2023
09:00

SESSION 5: NOVEL THERAPEUTIC APPROACHES (PRECLINICAL PERSPECTIVE) - Chairperson: Matthias Drosten

14 September
Time:  09:00 - 11:00
Location: 
09:00

New ideas to target RAS

Sala Mayor, Fonseca
René Bernards
Targeting RAS
14 September
Time:  09:00 - 09:30
Location:  Sala Mayor, Fonseca
Speaker:  René Bernards
09:30

Targeting KRAS signalling

Mariano Barbacid
Targeting RAS
14 September
Time:  09:30 - 10:00
Location: 
Speaker:  Mariano Barbacid
10:00

Drug repurposing strategies for the treatment of mutant KRAS cancers

Silve Vicent
Targeting RAS
14 September
Time:  10:00 - 10:30
Location: 
Speaker:  Silve Vicent
10:30

Understanding the role of endogenous and mutated KRAS in homeostasis and transformation of the colon

Owen Sansom
Targeting RAS
14 September
Time:  10:30 - 11:00
Location: 
Speaker:  Owen Sansom
11:00

Short talk selected from abstracts | Monica Musteanu, Universidad Complutense, Madrid, Spain “Avutometinib and FAK inhibitor concomitant treatment enhances antitumor efficacy of sotorasib in mice harboring KRASG12C;p53 mutant lung adenocarcinomas”

14 September
Time:  11:00 - 11:15
Location: 
11:15

Coffee break

14 September
Time:  11:15 - 11:45
Location: 
11:45

SESSION 6: NOVEL THERAPEUTIC APPROACHES (CLINICAL PERSPECTIVE) - Chairperson: Pilar Garrido

14 September
Time:  11:45 - 13:45
Location: 
11:45

Strategies for Drugging Undruggable Targets in Oncology With New Covalent Warheads

Kevan Shokat
Targeting RAS
14 September
Time:  11:45 - 12:15
Location: 
Speaker:  Kevan Shokat
12:15

Current and future challenges in the clinical development of KRAS G12C inhibitors in non-small cell lung cancer

Ernest Nadal
Targeting RAS
14 September
Time:  12:15 - 12:45
Location: 
Speaker:  Ernest Nadal
12:45

Luis Paz Ares (Hospital Universitario 12 de Octubre, Madrid, Spain)

Luis Paz-Ares
Targeting RAS
14 September
Time:  12:45 - 13:15
Location: 
Speaker:  Luis Paz-Ares
13:15

Applied biobanking to validate clinical vulnerabilities in RAS lung cancer variants

Colin Lindsay
Targeting RAS
14 September
Time:  13:15 - 13:45
Location: 
Speaker:  Colin Lindsay
13:45

Short talk selected from abstracts | Katrin J. Frank, Klinikum rechts der Isar, Technical University Munich, Germany “Combination of the novel SHP2 inhibitor RMC-4550 and the novel ERK inhibitor LY3214996 for the treatment of KRAS mutant pancreatic cancer”

14 September
Time:  13:45 - 14:00
Location: 
14:00

Lunch & poster session

14 September
Time:  14:00 - 15:15
Location: 
15:15

SESSION 7: NOVEL THERAPEUTIC APPROACHES (PHARMACEUTICAL PERSPECTIVE) - Chairperson: Julian Downward

14 September
Time:  15:15 - 17:15
Location: 
15:15

Using Tri-Complex RAS(ON) Inhibitors to Target RAS

Mathew Holderfield
Targeting RAS
14 September
Time:  15:15 - 15:45
Location: 
Speaker:  Mathew Holderfield
15:45

Progress on selective targeting of KRAS mutant alleles and emerging clinical implications

James Christensen
Targeting RAS
14 September
Time:  15:45 - 16:15
Location: 
Speaker:  James Christensen
16:15

Targeting RAS-Driven PI3Kα Activation in Human Tumors

Pedro Beltran
Targeting RAS
14 September
Time:  16:15 - 16:45
Location: 
Speaker:  Pedro Beltran
16:45

Targeting KRAS via SOS1: Parallel Fragment Screening and HTS Approach

Barbara Nicke
Targeting RAS
14 September
Time:  16:45 - 17:15
Location: 
Speaker:  Barbara Nicke
17:15

A clinical update on AMGEN's KRAS G12C-selective inhibitor Sotorasib and pre-clinical studies on a novel multi-KRAS inhibitor

Rati Verma
Targeting RAS
14 September
Time:  17:15 - 17:45
Location: 
Speaker:  Rati Verma
17:45

Short talk selected from abstracts | Barbara Mair, Boehringer Ingelheim RCV, Vienna, Austria “Assessment of KRAS mutant allele binding by covalent and non-covalent inhibitors through a cellular Switch-I/II and Switch-II pocket target engagement assay”

14 September
Time:  17:45 - 00:00
Location: 
18:00

Coffee break

14 September
Time:  18:00 - 18:30
Location: 
18:30

SESSION 8: TREATMENTS & COMBINATIONS TO COME (ROUND TABLE) - Chairperson: René Bernards

14 September
Time:  18:30 - 19:15
Location: 
18:30

Participants from pharma, clinic and academia (TBD)

14 September
Time:  18:30 - 19:15
Location: 
19:30

End of day 2

14 September
Time:  19:30 - 00:58
Location: 
20:30

Meeting dinner: Palacio de Figueroa - Calle Zamora, 15, 37002 Salamanca

14 September
Time:  20:30 - 22:30
15th september
15 September 2023
09:00

SESSION 9: RAS SYSTEMS BIOLOGY & NOVEL SIGNALLING FEATURES (I) - Chairperson: Silve Vicent

15 September
Time:  09:00 - 10:30
Location: 
09:00

A perfect storm - Formation of Ras - Raf signalosome and its implications

Yibing Shan
Targeting RAS
15 September
Time:  09:00 - 09:30
Location: 
Speaker:  Yibing Shan
09:30

Three Rs: RNA Regulates RAS-ERK signals

Piero Crespo
Targeting RAS
15 September
Time:  09:30 - 10:00
Location: 
Speaker:  Piero Crespo
10:00

The SHOC2/MRAS/PP1 complex as a therapeutic target for RAS-driven cancers

Pablo Rodríguez-Viciana
Targeting RAS
15 September
Time:  10:00 - 10:30
Location: 
Speaker:  Pablo Rodríguez-Viciana
10:30

Short talk selected from abstracts | Mukund Sharma, University of Turku, Finland “Convergence of RAS and PP2A activity on the phosphoregulation of chromatin repressor complexes”

15 September
Time:  10:30 - 10:45
Location: 
10:45

Coffee break

15 September
Time:  10:45 - 11:15
Location: 
11:15

SESSION 10: RAS SYSTEMS BIOLOGY & NOVEL SIGNALLING FEATURES (II) - Chairperson: Mariano Barbacid

15 September
Time:  11:15 - 12:45
Location: 
11:15

Back to the future: the role of RAF kinases in RAS signaling and transformation

Walter Kolch
Targeting RAS
15 September
Time:  11:15 - 11:45
Location: 
Speaker:  Walter Kolch
11:45

Targeting the KRAS-ERK-MYC signaling network for the treatment of KRAS-mutant pancreatic cancer

Channing J. Der
Targeting RAS
15 September
Time:  11:45 - 12:15
Location: 
Speaker:  Channing J. Der
12:15

Ras-effector networks in (patho)physiological contexts

Christina Kiel
Targeting RAS
15 September
Time:  12:15 - 12:45
Location: 
Speaker:  Christina Kiel
12:45

Short talk selected from abstracts | Patricia Santofimia Castaño, Centre de Recherche en Cancérologie de Marseille, INSERM, France “Targeting NUPR1-dependet Stress Granules Formation as an Efficient Strategy to Induce Synthetic Lethality In KrasG12D-Dependent Tumors”

15 September
Time:  12:45 - 13:00
Location: 
13:00

SESSION 11: CLOSING LECTURE

15 September
Time:  13:00 - 13:45
Location: 
13:00

The End of KRAS cancers?

Frank McCormick
Targeting RAS
15 September
Time:  13:00 - 13:30
Location: 
Speaker:  Frank McCormick
13:45

End of meeting

15 September
Time:  13:45 - 15:00

Targeting RAS
New challenges
and avenues

Contact

Symposium

Registration

You may need

PROGRAM
SPEAKERS
rEGISTRATION
SPONSORS